Hyperthyroidism Clinical Trial Landscape
Data updated: May 20, 2026
26 clinical trials tracked since 2008
Hyperthyroidism is being studied across 26 clinical trials registered since 2008, with 10 programs currently active. The competitive pipeline includes 3 active Phase 3 trials, 2 active Phase 2 trials, and 4 active Phase 1 trials. Top industry sponsors include argenx, Biohaven Therapeutics Ltd., Merida Biosciences.
10 active
/
26 total (since 2008)
4
Phase 1 Active
7 total
2
Phase 2 Active
6 total
3
Phase 3 Active
7 total
2
Phase 4 Active
8 total
Top Industry Sponsors
Sorted by active Active Done Failed
argenx 2 0 0
Biohaven Therapeutics Ltd. 1 0 0
Merida Biosciences 1 0 0
Changchun GeneScience Pharmaceutical Co., Ltd. 1 0 0
Featured Phase 3 Trials
NCT04856488 RECRUITING
Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter
Jan Calissendorff n=182
NCT05118542 COMPLETED
Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis
Indonesia University n=36
NCT01295333 COMPLETED
Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance
Assistance Publique Hopitaux De Marseille n=200
NCT07570316 NOT YET RECRUITING
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
argenx n=230
NCT07596849 NOT YET RECRUITING
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
argenx n=230
+ 2 more Phase 3 trials — see full database below
Hyperthyroidism — Trials Started by Year (last 10 years)
2016 1
2017 1
2018 1
2019 4
2020 0
2021 3
2022 1
2023 2
2024 0
2025 4
2026 3
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
argenx 2
Biohaven Therapeutics Ltd. 1
Merida Biosciences 1
Changchun GeneScience Pharmaceutical Co., Ltd. 1
Immunovant Sciences GmbH 1
Apitope International NV 1
Active Trials by Phase
Phase 1 4
Phase 2 2
Phase 3 3
Phase 4 2
Enrollment Size Distribution
1-50 14
51-200 8
201-500 3
501-1k 1
1k+ 0
All Industry Sponsors
Sorted by active Active Done Failed
argenx 2 0 0
Biohaven Therapeutics Ltd. 1 0 0
Merida Biosciences 1 0 0
Changchun GeneScience Pharmaceutical Co., Ltd. 1 0 0
NCT07570316 NOT YET RECRUITING
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
argenx n=230
NCT04856488 RECRUITING
Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter
Jan Calissendorff n=182
NCT07596849 NOT YET RECRUITING
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
argenx n=230
NCT05142904 TERMINATED
Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules
Rijnstate Hospital n=40
NCT04080505 TERMINATED
Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?
Columbia University n=29
NCT05118542 COMPLETED
Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis
Indonesia University n=36
NCT01295333 COMPLETED
Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance
Assistance Publique Hopitaux De Marseille n=200
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only